Adaptive Biotechnologies Corporation (ADPT)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Adaptive Biotechnologies Corporation has not issued a press release in this window.
SEC filings
All filings →Adaptive Biotechnologies Corporation has not filed an SEC document in this window.
Insider trades
All insider trades →Adaptive Biotechnologies Corporation has no reported insider trades in the last 90 days.